Evolution of patient derived xenograft acute myeloid leukaemia subclones in a preclinical mouse model (A05)

• Subject Area: Hematology, Oncology
• Term: from 2016 to 2020
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 278529602

The subclone with the most adverse characteristics determines prognosis of the patient. To identify and characterize adverse subclones, we use the individualized patient-derived xenograft (PDX) mouse model of acute myeloid leukemia (AML) complemented with genetic engineering. In the current funding period, we applied genetic barcoding and described adverse subclones with aggressive behavior upon spontaneous tumor growth. In the upcoming funding period, we will concentrate on adverse subclones appearing upon selection pressure by treatment.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1243: Genetic and Epigenetic Evolution of Hematopoietic Neoplasms
• Applicant Institution: Ludwig-Maximilians-Universität München
• Project Head: Professorin Dr. Irmela Jeremias, Ph.D.